Cathie Wood Buys Beam Therapeutics for 8th Consecutive Day
Cathie Wood's flagship ARK Innovation ETF has been buying Beam Therapeutics Inc. for eight consecutive days, with the stock soaring 14% as a result. The fund's bold move is drawing attention from investors and analysts alike, who are weighing in on the merits of Wood's strategy. However, some experts remain skeptical, citing concerns over risk management and portfolio concentration.
- Cathie Wood's aggressive buying sprees may be a reflection of her faith in the long-term potential of genomics and precision medicine, but they also raise questions about the sustainability of her approach.
- As investors continue to scrutinize ARK Invest's holdings and strategy, will Cathie Wood's unorthodox approach ultimately pay off, or will it prove to be a costly gamble for her fund?